查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1224527

美国癌症活检市场规模、份额和趋势分析报告：按类型（细针穿刺、核心、手术、皮肤活检/穿刺活检）、应用、站点、细分市场预测 2023-2030 年

U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), By Application, By Site, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 155 Pages | 商品交期: 2-10个工作天内

价格

美国癌症活检市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告预测，从 2023 年到 2030 年，美国癌症活检市场将以 11.12% 的复合年增长率增长，到 2030 年将达到 201.8 亿美元。 美国癌症活检市场的增长归因于越来越多地采用基于多参数磁共振成像的活检以及图像引导穿刺活检在精准医学应用中的日益普及。

液体活检行业预计在未来几年呈指数级增长，参与生物製药製造和基因组数据分析的公司不断增加投资和战略举措，预计将发挥核心作用。事实一直如此。 2022 年 4 月，Sekai-Brain 投资 Craif 开发一种用于早期检测癌症的新型非侵入性液体尿液活检。

此外，液体活检的出现、活检临床实践的增加以及遗传性癌症疾病质量和支付的进步是预计在未来几年推动市场增长的因素。 癌症患病率上升和老年人口增加也有望推动市场增长。

此外，基于血液的多发性癌症早期检测 (MCED) 技术的出现有望在预测期内提供有利可图的机会。 MCED 代表了未来癌症诊断和治疗方式的范式转变。 MCED 带来的巨大希望是，它将使临床医生能够从筛查少数癌症转移到筛查大量癌症。

GRAIL 和 Exact Sciences 等公司正在开发 MCED 测试。 此外，美国国家癌症研究所 (NCI) 正在考虑研究和评估 MCED 测试的方法。 NCI 目前正在为 MCED 测试设计临床试验和其他研究机会，并且最近向测试开发人员发出了关于他们参与研究计划的意愿的信息请求。

美国癌症活检市场的主要参与者已采取多项战略举措来加强其市场占有率。 市场进入者的主要举措包括併购、合作与伙伴关係、地域扩张和新产品发布。 例如，2022 年 4 月，Medtronic开始与 GE Healthcare 合作，以满足日益增长的门诊护理需求。 在此计划下，客户将可以获得金融解决方案、丰富的产品组合和卓越的服务。

美国癌症活检市场报告要点

由于它是一种确定不确定组织状况的有效且快速的测试，因此细针抽吸将在 2022 年主导市场

由于对候选新药开发的需求不断增长，预计在预测期内，製药和生物製药的发现和开发板块将以最快的速度增长

乳腺癌患病率上升将使乳腺癌细分市场成为 2022 年美国癌症活检市场创收最高的细分市场

由于政府采取预防措施阻止疾病进展，北美将在 2022 年主导美国癌症活检市场

内容

第一章调查方法及范围

  • 调查方法
  • 调查假设
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
      • 初步调查
    • 初步调查的详细信息
  • 信息或数据分析
    • 数据分析模型
      • 最终用途景观评估
      • 市场来源评估
      • 肿瘤诊断：市场竞争分析
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 美国市场：CAGR 计算
  • 二级信息列表
  • 主要信息列表
  • 目的

第 2 章执行摘要

  • 市场展望

第 3 章市场变量、趋势和范围

  • 美国和国际癌症医疗旅游
  • 市场驱动因素分析
    • 液体活检的出现
    • 将新的肿瘤学诊断方法从实验台转移到临床
    • 提高癌症基因检测的质量和费用
  • 市场製约因素分析
    • 与活检程序相关的风险
    • 技术和临床挑战
  • 市场机会分析
    • 活检在肿瘤学伴随诊断中的重要作用
    • 转化研究中对活组织检查的需求不断增加
  • 市场威胁分析
    • 与重复活检程序相关的风险

第四章营商环境分析

  • SWOT 分析；按因素（政治和法律、经济、技术）
  • 波特的五力分析

第五章供应链分析

  • 样品采集（生物样本库中心列表）
  • 样品处理（供应商列表）

第六章成本/价格分析

  • 活检费用
    • 根据指示
      • 美国医疗保险未涵盖的患者的典型活检费用
    • 按类型和方法
  • 影响成本的主要因素
  • 癌症管理的成本
    • 癌症治疗药物和诊断的价格分析
    • 美国在癌症方面的支出（按支付来源）

第 7 章报销和监管分析

  • 监管框架：美国癌症活检市场
  • 报销框架：美国癌症活检市场

第 8 章问题/约束/并发症分析

  • 问题/制约因素/并发症分析
    • 按地区（器官）
    • 通过方法

第9章癌症活检产品製造商

第10章类型业务分析

  • 美国癌症活检市场：类型变异分析
  • 美国癌症活检市场：活检类型比较分析
  • 细针穿刺
  • 穿刺活检 (CNB)
  • 癌症手术活检
  • 皮肤活检/穿刺活检
  • 其他

第11章站点（器官）业务分析

  • 癌症活检市场：部位（器官）变异分析
  • 胸部
  • 甲状腺
  • 子宫和子宫颈
  • 肺
  • 前列腺
  • 膀胱
  • 肾臟
  • 肝臟
  • 胰腺
  • 其他网站

第12章应用（原因）业务分析

  • 美国癌症活检市场：提交（原因）变异分析
  • 筛查和监测
  • 诊断
  • 研究和转化研究
  • 医药和生物製药的发现和开发

第13章区域业务分析

  • 美国癌症活检市场：区域差异分析
  • 美国

第14章竞争格局

  • 市场参与分类
  • 战略框架
  • 供应商情况
    • 主要分销商和渠道合作伙伴列表
    • 主要客户
      • 主要客户名单
    • 上市公司
      • 上市公司名单
    • 私人公司
      • 主要私营公司名单
    • 新兴玩家
      • 主要初创企业名单
  • 对主要交易和战略联盟的分析
    • 併购
    • 合作与伙伴关係
    • 新产品发布
  • 主要参与者的市场影响分析
    • 安索夫矩阵
    • 公司/竞争对手分类（一级和二级市场进入者）

第十五章公司简介

  • 公司简介
    • Bd（Becton, Dickinson And Company）
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Izi Medical Products
      • 公司概况
      • 产品基准
      • 战略举措
    • Johnson &Johnson Services, Inc.
      • 公司概况
      • Depuy Synthes
      • 公司概况
      • Ethicon, Inc.
      • 公司概况
      • 财务业绩
      • 产品基准
    • Argon Medical
      • 公司概况
      • 产品基准
      • 战略举措
      • Cook
      • 公司概况
      • 产品基准
    • Spectra Medical Devices, Inc.
      • 公司概况
      • 产品基准
    • Medtronic
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Boston Scientific Corporation
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
    • Conmed Corporation
      • 公司概况
      • 财务业绩
      • 产品基准
    • Inrad, Inc.
      • 公司概况
      • 产品基准
    • Thermo Fisher Scientific, Inc.
      • 公司概况
      • 财务业绩
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-467-3

U.S. Cancer Biopsy Market Growth & Trends:

The U.S. cancer biopsy market is expected to reach USD 20.18 billion by 2030, registering a CAGR of 11.12% from 2023 to 2030 according to a new report by Grand View Research, Inc. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.

The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.

Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.

Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.

Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.

Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.

U.S. Cancer Biopsy Market Report Highlights:

  • Fine-needle aspiration segment held a dominant share in 2022 owing to the effective and quick test for determining the status of uncertain tissue
  • Pharma & biopharma discovery & development segment is projected to grow at the fastest rate during the forecast period owing to the increasing demand for developing novel drug candidates
  • Breast cancer segment is the highest revenue-generating segment in the U.S. cancer biopsy market in 2022 owing to the increasing prevalence of breast cancer
  • North America dominated the U.S. cancer biopsy market in 2022, which is attributed to preventive measures undertaken by the governments to stop the progression of diseases

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
      • 1.4.3.1 Primary Research
    • 1.4.4 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
      • 1.5.1.1 End-Use Landscape Assessment
      • 1.5.1.2 Market Origin Assessment
      • 1.5.1.3 Oncology Diagnosis: Market Competition Analysis
  • 1.6 Market Formulation And Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.8 U.S. Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Market Variables, Trends, and Scope

  • 3.1 Cancer Medical Tourism Within & Outside the U.S.
  • 3.2 Market Driver Analysis
    • 3.2.1 Advent Of Liquid Biopsy
    • 3.2.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
    • 3.2.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
  • 3.3 Market Restraint Analysis
    • 3.3.1 Risks Associated With Biopsy Procedures
    • 3.3.2 Technical And Clinical Challenges
  • 3.4 Market Opportunity Analysis
    • 3.4.1 Integral Role Of Biopsies In Oncology Companion Diagnostics
    • 3.4.2 Increase In The Demand For Biopsies In Translational Research
  • 3.5 Market Threat Analysis
    • 3.5.1 Risk Associated With Repeat Biopsy Procedures

Chapter 4 Business Environment Analysis

  • 4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
  • 4.2 Porter's Five Forces Analysis

Chapter 5 Supply Chain Analysis

  • 5.1 Sample Collection (List of Biobanks/Center)
  • 5.2 Sample Processing (List of Vendors)

Chapter 6 Cost/Pricing Analysis

  • 6.1 Biopsy Cost
    • 6.1.1 By Indication
      • 6.1.1.1 Typical Biopsy Costs For Patients Not Covered By Health Insurance In The U.S.
    • 6.1.2 By Type/Method
  • 6.2 Key Factors Influencing The Cost
  • 6.3 Costs Of Cancer Management
    • 6.3.1 Pharma Versus Diagnostics Price Analysis For Cancer Care
    • 6.3.2 U.S. Expenditures For Cancer By Source Of Payment
      • 6.3.2.1 Expenditures For Cancer Care By Year & Cancer Site, USD Million, 2010 - 2018

Chapter 7 Reimbursement And Regulatory Analysis

  • 7.1 Regulatory Framework: U.S. Cancer Biopsy Market
  • 7.2 Reimbursement Framework: U.S. Cancer Biopsy Market

Chapter 8 Challenges/Restraints/Complications Analysis

  • 8.1 Challenges/Restraints/Complications Analysis
    • 8.1.1 By Site (Organ)
    • 8.1.2 By Method

Chapter 9 Cancer Biopsy Product Manufacturers

Chapter 10 Type Business Analysis

  • 10.1 U.S. Cancer Biopsy Market: Type Movement Analysis
  • 10.2 U.S. Cancer Biopsy Market: Comparative Analysis of Biopsy Type
  • 10.3 Fine Needle Aspiration
  • 10.4 Core Needle Biopsy (CNB)
    • 10.4.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.1.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.4.1.2 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
  • 10.5 Cancer Surgical Biopsy
    • 10.5.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.1.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.5.1.2 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
  • 10.6 Skin Biopsy/Punch Biopsy
    • 10.6.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.6.1.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.6.1.2 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
      • 10.6.1.3 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.6.1.4 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.6.1.5 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
  • 10.7 Others
    • 10.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Types, 2018 - 2030 (USD Million)
      • 10.7.1.1 U.S. other types cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
      • 10.7.1.2 U.S. other types cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

Chapter 11 Site (Organ) Business Analysis

  • 11.1 Cancer Biopsy Market: Site (Organ) Movement Analysis
  • 11.2 Breast
    • 11.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Breast, 2018 - 2030 (USD Million)
  • 11.3 Thyroid
    • 11.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Thyroid, 2018 - 2030 (USD Million)
  • 11.4 Uterus & Cervix
    • 11.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Uterus & Cervix, 2018 - 2030 (USD Million)
  • 11.5 Lung
    • 11.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Lung, 2018 - 2030 (USD Million)
  • 11.6 Prostate
    • 11.6.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Prostate, 2018 - 2030 (USD Million)
  • 11.7 Bladder
    • 11.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Bladder, 2018 - 2030 (USD Million)
  • 11.8 Kidney
    • 11.8.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Kidney, 2018 - 2030 (USD Million)
  • 11.9 Liver
    • 11.9.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Liver, 2018 - 2030 (USD Million)
  • 11.10 Pancreas
    • 11.10.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pancreas, 2018 - 2030 (USD Million)
  • 11.11 Other Sites
    • 11.11.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Sites, 2018 - 2030 (USD Million)

Chapter 12 Application (Cause) Business Analysis

  • 12.1 U.S. Cancer Biopsy Market: Application (Cause) Movement Analysis
  • 12.2 Screening & Monitoring
    • 12.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Screening & Monitoring, 2018 - 2030 (USD Million)
  • 12.3 Diagnostics
    • 12.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Diagnostics, 2018 - 2030 (USD Million)
  • 12.4 Investigational & Translational Research
    • 12.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Investigational & Translational Research, 2018 - 2030 (USD Million)
  • 12.5 Pharma & Biopharma Discovery & Development
    • 12.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pharma & Biopharma Discovery & Development, 2018 - 2030 (USD Million)

Chapter 13 Regional Business Analysis

  • 13.1 U.S. Cancer Biopsy Market: Regional Movement Analysis
  • 13.2 U.S.
    • 13.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)

Chapter 14 Competitive Landscape

  • 14.1 Market Participation Categorization
  • 14.2 Strategy Framework
  • 14.3 Vendor Landscape
    • 14.3.1 List Of Key Distributors And Channel Partners
    • 14.3.2 Key Customers
      • 14.3.2.1 List Of Key Customers
    • 14.3.3 Public Companies
      • 14.3.3.1 List Of Public Companies
    • 14.3.4 Private Companies
      • 14.3.4.1 List Of Key Private Companies
    • 14.3.5 Emerging Players
      • 14.3.5.1 List Of Key Emerging Companies
  • 14.4 Major Deals And Strategic Alliances Analysis
    • 14.4.1 Mergers And Acquisitions
    • 14.4.2 Collaborations And Partnerships
    • 14.4.3 New Product Launch
  • 14.5 Market Impact Analysis By Key Participants
    • 14.5.1 Ansoff Matrix
    • 14.5.2 Company/Competition Categorization (Primary & Secondary Market Participants)

Chapter 15 Company Profiles

  • 15.1 Company Profiles
    • 15.1.1 Bd (Becton, Dickinson And Company)
      • 15.1.1.1 Company Overview
      • 15.1.1.2 Financial Performance
      • 15.1.1.3 Product Benchmarking
      • 15.1.1.4 Strategic Initiatives
    • 15.1.2 Izi Medical Products
      • 15.1.2.1 Company Overview
      • 15.1.2.2 Product Benchmarking
      • 15.1.2.3 Strategic Initiatives
    • 15.1.3 Johnson & Johnson Services, Inc.
      • 15.1.3.1 Company Overview
      • 15.1.3.2 Depuy Synthes
      • 15.1.3.2.1 Company Overview
      • 15.1.3.3 Ethicon, Inc.
      • 15.1.3.3.1 Company Overview
      • 15.1.3.4 Financial Performance
      • 15.1.3.5 Product Benchmarking
    • 15.1.4 Argon Medical
      • 15.1.4.1 Company Overview
      • 15.1.4.2 Product Benchmarking
      • 15.1.4.3 Cook
      • 15.1.4.4 Company Overview
      • 15.1.4.5 Product Benchmarking
    • 15.1.5 Spectra Medical Devices, Inc.
      • 15.1.5.1 Company Overview
      • 15.1.5.2 Product Benchmarking
    • 15.1.6 Medtronic
      • 15.1.6.1 Company Overview
      • 15.1.6.2 Financial Performance
      • 15.1.6.3 Product Benchmarking
      • 15.1.6.4 Strategic Initiatives
    • 15.1.7 Boston Scientific Corporation
      • 15.1.7.1 Company Overview
      • 15.1.7.2 Financial Performance
      • 15.1.7.3 Product Benchmarking
      • 15.1.7.4 Strategic Initiatives
    • 15.1.8 Conmed Corporation
      • 15.1.8.1 Company Overview
      • 15.1.8.2 Financial Performance
      • 15.1.8.3 Product Benchmarking
    • 15.1.9 Inrad, Inc.
      • 15.1.9.1 Company Overview
      • 15.1.9.2 Product Benchmarking
    • 15.1.10 Thermo Fisher Scientific, Inc.
      • 15.1.10.1 Company Overview
      • 15.1.10.2 Financial Performance
      • 15.1.10.3 Product Benchmarking
      • 15.1.10.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Reasons for the popularity of oncology tourism in some countries
  • Table 3 Common types of oncology tourism treatments
  • Table 4 Liquid biopsy developing or commercializing companies
  • Table 5 Average pricing analysis: Biopsy to indication
  • Table 6 Average pricing analysis: Biopsy to indication
  • Table 7 Expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
  • Table 8 List of cleared/approved companion diagnostic devices (In vitro and imaging tools)
  • Table 9 Types of insurance coverage
  • Table 10 Policy structure types issued by private payers and Medicare
  • Table 11 Coverage policies for ctDNA
  • Table 12 CPT codes for minimally invasive prostate procedures
  • Table 13 CPT codes for office visits-new & established patient
  • Table 14 Surgical biopsy: Feasibility analysis across cancer diagnosis
  • Table 15 Comparative analysis of traditional and liquid liver biopsies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 End-use landscape: Cancer biopsy product penetration
  • Fig. 5 Cancer biopsy: Market origin/parent market assessment
  • Fig. 6 Market competition analysis: Early diagnosis industry sector
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. cancer biopsy market outlook (2022)
  • Fig. 9 U.S. cancer biopsy market driver impact
  • Fig. 10 External factors driving the demand for cancer biopsy
  • Fig. 11 U.S. cancer biopsy market restraint impact
  • Fig. 12 SWOT analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Key driving factors of biopsy costs
  • Fig. 15 U.S. expenditures for cancer by payment source, 2018
  • Fig. 16 National cancer costs projected to increase drastically by 2030, in USD Billion
  • Fig. 17 U.S. out-of-pocket expenses 2014 vs. 2018
  • Fig. 18 U.S. cancer management expenditure
  • Fig. 19 U.S. cancer biopsy market: Type outlook and key takeaways
  • Fig. 20 U.S. cancer biopsy market: Type movement analysis
  • Fig. 21 Tissue biopsy vs liquid biopsy: Comparative analysis
  • Fig. 22 U.S. cancer core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. cancer core needle biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. cancer core needle biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. cancer surgical biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. cancer surgical biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. cancer surgical biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. skin biopsy/punch cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U. S .skin biopsy /punch cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. cancer liquid biopsy market estimates and forecasts for other types, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. other types of cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. other types of cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 37 Cancer biopsy market: Site (Organ) outlook and key takeaways
  • Fig. 38 Cancer biopsy market: Site (Organ) movement analysis
  • Fig. 39 U.S. cancer biopsy market estimates and forecasts for breast, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. cancer biopsy market estimates and forecasts for thyroid, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. cancer biopsy market estimates and forecasts for uterus & cervix, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. cancer biopsy market estimates and forecasts for lung, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. cancer biopsy market estimates and forecasts for prostate, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. cancer biopsy market estimates and forecasts for bladder, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. cancer biopsy market estimates and forecasts for kidney, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. cancer biopsy market estimates and forecasts for liver, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. cancer biopsy market estimates and forecasts for pancreas, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. cancer biopsy market estimates and forecasts for other sites, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. cancer biopsy market: Application (Cause) outlook and key takeaways
  • Fig. 50 U.S. cancer biopsy market: Application (Cause) movement analysis
  • Fig. 51 U.S. cancer biopsy market estimates and forecasts for screening & monitoring, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. cancer biopsy market estimates and forecasts for diagnostics, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. cancer biopsy market estimates and forecasts for investigational & translational research, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. cancer biopsy market estimates and forecasts for pharma & biopharma discovery & development, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. cancer biopsy market, 2018 - 2030 (USD million)
  • Fig. 56 Participant categorization - U.S. cancer biopsy market
  • Fig. 57 Strategy framework - U.S. cancer biopsy market
  • Fig. 58 Ansoff matrix
  • Fig. 59 Competition categorization